PSA (prostate specific antigen)  
**MEN ONLY**

**Relevant cancer:** Prostate cancer

**Typical clinical presentations that might warrant measurement:**
Frequency, urgency, nocturia, dysuria, acute retention, back pain, weight loss, anaemia, prostate enlargement.

**Caution – other benign conditions marker may be raised in:**
Benign prostatic hyperplasia, urinary tract infection, prostatitis and after catheterisation.

**Caution – other malignancies marker may be raised in:**
None known.

**Notes**
- Take samples prior to digital rectal examination and >6 weeks after invasive procedures (e.g. prostatectomy)
- Objective information for asymptomatic men requesting PSA measurement is available at www.cancerscreening.nhs.uk.

CA125 (cancer antigen 125)  
**WOMEN ONLY**

**Relevant cancer:** Ovarian cancer

**Typical clinical presentations that might warrant measurement:**
Pelvic mass; persistent (more than 12 times / month) and continuous or worsening unexplained abdominal or urinary symptoms, abdominal bloating, increased urinary frequency

**Caution – other benign conditions marker may be raised in:**
Pregnancy, menstruation, endometriosis, benign ascites, acute hepatitis, chronic renal failure, heart failure, pleural effusion and others.

**Caution – other malignancies marker may be raised in:**
Breast, cervical, endometrial, hepatocellular, lung, pancreatic and other cancers.

**Notes**
- NICE recommends CA125 be measured in women with the symptoms above. Women with CA125 >35 kU/L should be referred for pelvic ultrasound. Women with CA125 ≤ 35 kU/L whose symptoms persist must be reassessed at 6 weeks.

CEA (carcinoembryonic antigen)  

**Relevant cancer:** Colorectal cancer

**Typical clinical presentations that might warrant measurement:**
Follow-up and monitoring of patients with colorectal cancer. Not recommended for diagnosis

**Caution – other benign conditions marker may be raised in:**
Irritable bowel syndrome, jaundice, hepatitis, chronic renal failure, pleural inflammation and others.

**Caution – other malignancies marker may be raised in:**
Breast, gastric, lung, medullary thyroid carcinoma, mesothelioma, oesophageal, pancreatic and other cancers.

**Notes**
- CEA is most appropriately used for monitoring colorectal cancer patients and detecting recurrence. CEA should be measured at 2 to 3 monthly intervals following treatment.
- CEA measurement may very occasionally be helpful in frail elderly patients in whom cancer is suspected.
Tumour Marker Requesting
Guidance for Non Specialists

**AFP & hCG** (α-fetoprotein, human chorionic gonadotrophin)

**Relevant cancer:** Testicular / germ cell cancer

**Typical clinical presentations that might warrant measurement:** Diffuse testicular swelling, hardness and pain at any age.

**Caution – other conditions marker may be raised in:** Liver regeneration, hepatitis, benign liver disease (AFP), pregnancy (hCG).

**Caution – other malignancies marker may be raised in:** Hepatocellular, colorectal, gastric, lung and other cancers.

**Notes**
- When requesting paraprotein investigations please send both a serum and a urine specimen. Some laboratories use serum free light chain measurement to help screen for paraproteins but urine investigation may still be required at a later stage.

**Top tips for optimal requesting**
- The need for informed consent should be considered.
- Opportunistic screening with panels of tumour markers is not helpful. CA125 should not be measured in men nor PSA in women.
- Serial results are usually most useful as the main application of serum tumour markers is in monitoring patients with a previously diagnosed malignancy.
- Provision of brief and relevant clinical information on the request form is very helpful to the laboratory.
- CA 15-3 and CA19-9 should only be requested as and when advised by the specialist secondary care team. This should be indicated on the request form.
- Laboratory staff are always pleased to provide advice on test requesting and interpretation.

**Useful resources**
- **General:** 'Serum tumour markers: how to order and interpret them' http://tinyurl.com/TumourMarkers
- **General:** www.labtestsonline.org.uk
- **PSA:** www.cancerscreening.nhs.uk/prostate/
- **CA125:** http://guidance.nice.org.uk/CG122
- **Paraproteins:** http://tinyurl.com/Paraproteins
- **AFP & hCG:** www.sign.ac.uk/pdf/sign124.pdf

---

**Paraproteins** (M-Protein)

**Relevant cancer:** B-cell proliferative disorders (e.g. multiple myeloma, AL-amyloidosis, Waldenstrom’s macroglobulinaemia and some low grade non-Hodgkin’s lymphomas).

**Typical clinical presentations that might warrant measurement:** Unexplained anaemia, bone pain, weakness or fatigue, raised ESR, viscosity or abnormal globulins, hypercalcaemia, renal failure, spontaneous fractures and/or recurrent infections.

**Notes**
- As well as contributing to diagnosis, AFP and hCG measurements are mandatory in the post-treatment monitoring of germ cell tumours following well-defined protocols that depend on stage and treatment.

---

**AFP & hCG** (α-fetoprotein, human chorionic gonadotrophin)

**Relevant cancer:** Testicular / germ cell cancer

**Typical clinical presentations that might warrant measurement:** Diffuse testicular swelling, hardness and pain at any age.

**Caution – other conditions marker may be raised in:** Liver regeneration, hepatitis, benign liver disease (AFP), pregnancy (hCG).

**Caution – other malignancies marker may be raised in:** Hepatocellular, colorectal, gastric, lung and other cancers.

**Notes**
- When requesting paraprotein investigations please send both a serum and a urine specimen. Some laboratories use serum free light chain measurement to help screen for paraproteins but urine investigation may still be required at a later stage.

---

**Tumour Marker Requesting**

**Guidance for Non Specialists**

**Top tips for optimal requesting**
- The need for informed consent should be considered.
- Opportunistic screening with panels of tumour markers is not helpful. CA125 should not be measured in men nor PSA in women.
- Serial results are usually most useful as the main application of serum tumour markers is in monitoring patients with a previously diagnosed malignancy.
- Provision of brief and relevant clinical information on the request form is very helpful to the laboratory.
- CA 15-3 and CA19-9 should only be requested as and when advised by the specialist secondary care team. This should be indicated on the request form.
- Laboratory staff are always pleased to provide advice on test requesting and interpretation.

**Useful resources**
- **General:** 'Serum tumour markers: how to order and interpret them' http://tinyurl.com/TumourMarkers
- **General:** www.labtestsonline.org.uk
- **PSA:** www.cancerscreening.nhs.uk/prostate/
- **CA125:** http://guidance.nice.org.uk/CG122
- **Paraproteins:** http://tinyurl.com/Paraproteins
- **AFP & hCG:** www.sign.ac.uk/pdf/sign124.pdf

© Pathology Harmony, June 2012 Version 1.0

pathologyharmony.co.uk working to harmonise standards in UK pathology